Histogen Inc (NASDAQ: HSTO) announced the beginning of its Stage 1/2 scientific pilot of HST 003 to assess the security and efficiency of human extracellular medium (hECM: HST 003). It is inserted within microfracture spaces and the tendon flaw in the knee to restore hyaline gristle combined with a microfracture […]